MicroRNA-145-5p suppresses cell proliferation, migration, and invasion in upper tract urothelial carcinoma by targeting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase.
ATIC
miR-145-5p
prognosis
upper tract urothelial carcinoma
Journal
Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
04
07
2023
received:
26
04
2023
accepted:
10
07
2023
medline:
22
9
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
Upper tract urothelial carcinoma (UTUC), including renal, pelvic, and ureteral carcinoma, has a high incidence rate in Taiwan, which is different from that in Western countries. Therefore, it is imperative to elucidate the mechanisms underlying UTUC growth and metastasis. To explore the function of miR-145-5p in UTUC, we transfected the BFTC909 cell line with miR-145-5p mimics and analyzed the differences in protein levels by performing two-dimensional polyacrylamide gel electrophoresis. Real-time polymerase chain reaction and Western blot analysis were used to analyze 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inositol monophosphate cyclohydrolase (ATIC) messenger RNA and protein levels. A dual-luciferase assay was performed to identify the target of miR-145-5p in ATIC. The effects of miR-145-5p and ATIC expression by cell transfection on cell proliferation, migration, and invasion were also assessed. miR-145-5p downregulated ATIC protein expression. High ATIC expression is associated with tumor stage, metastasis, recurrence, and a poor prognosis in patients with UTUC. Cell function assays revealed that ATIC knockdown inhibited the proliferation, migration, and invasive abilities of UTUC cells. In contrast, miR-145-5p affected the proliferation, migration, and invasive abilities of UTUC cells by directly targeting the 3'-untranslated regions of ATIC. Furthermore, we used RNA sequencing and Ingenuity Pathway Analysis to identify possible downstream genes regulated by ATIC and found that miR-145-5p regulated the protein levels of fibronectin 1, Slug, cyclin A2, cyclin B1, P57, and interferon-induced transmembrane 1 via ATIC. ATIC may be a valuable predictor of prognosis and a potential therapeutic target for UTUC.
Substances chimiques
MicroRNAs
0
IMP cyclohydrolase
EC 3.5.4.10
4-aminoimidazole
4919-03-3
Hydroxymethyl and Formyl Transferases
EC 2.1.2.-
Ribonucleotides
0
MIRN145 microRNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1324-1345Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Jazayeri SB, Liu JS, Weissman B, Lester J, Samadi DB, Feuerstein MA. Comparison of adjuvant chemotherapy for upper tract versus lower tract urothelial carcinoma: a systematic review and meta-analysis. Curr Urol. 2019;12:177-187. doi:10.1159/000499308
Green DA, Rink M, Xylinas E, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol. 2013;189:1214-1221. doi:10.1016/j.juro.2012.05.079
Luo H-L, Chen T-S, Wu W-J. The cancer behavior and current treatment strategy for upper urinary tract cancer. Urol Sci. 2022;33:161-169. doi:10.4103/uros.Uros_58_22
Wu YT, Luo HL, Wang HJ, Chen YT, Cheng YT, Chiang PH. Gender effect on the oncologic outcomes of upper urinary tract urothelial carcinoma in Taiwan. Int Urol Nephrol. 2020;52:1043-1048. doi:10.1007/s11255-020-02396-z
Yang K, Yu W, Liu H, et al. Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder. Oncologist. 2021;26:e1395-e1405. doi:10.1002/onco.13839
Hassler MR, Bray F, Catto JWF, et al. Molecular characterization of upper tract urothelial carcinoma in the era of next-generation sequencing: a systematic review of the current literature. Eur Urol. 2020;78:209-220. doi:10.1016/j.eururo.2020.05.039
Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3:83-92.
Pu M, Chen J, Tao Z, et al. Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression. Cell Mol Life Sci. 2019;76:441-451. doi:10.1007/s00018-018-2940-7
Kilikevicius A, Meister G, Corey DR. Reexamining assumptions about miRNA-guided gene silencing. Nucleic Acids Res. 2022;50:617-634. doi:10.1093/nar/gkab1256
Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol: Mech Dis. 2014;9:287-314. doi:10.1146/annurev-pathol-012513-104715
Cui SY, Wang R, Chen LB. MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J Cell Mol Med. 2014;18:1913-1926. doi:10.1111/jcmm.12358
Kadkhoda S, Ghafouri-Fard S. Function of miRNA-145-5p in the pathogenesis of human disorders. Pathol Res Pract. 2022;231:153780. doi:10.1016/j.prp.2022.153780
Hsu WC, Li WM, Lee YC, et al. MicroRNA-145 suppresses cell migration and invasion in upper tract urothelial carcinoma by targeting ARF6. FASEB J. 2020;34:5975-5992. doi:10.1096/fj.201902555R
Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27-47. doi:10.1016/j.cmet.2015.12.006
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022;12:31-46. doi:10.1158/2159-8290.CD-21-1059
Yin J, Ren W, Huang X, Deng J, Li T, Yin Y. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol. 2018;9:1697. doi:10.3389/fimmu.2018.01697
Villa E, Ali E, Sahu U, Ben-Sahra I. Cancer cells tune the signaling pathways to empower de novo synthesis of nucleotides. Cancers. 2019;11:688. doi:10.3390/cancers11050688
Moffatt BA, Ashihara H. Purine and pyrimidine nucleotide synthesis and metabolism. Arabidopsis Book. 2002;1:e0018. doi:10.1199/tab.0018
Robinson AD, Eich ML, Varambally S. Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. Cancer Lett. 2020;470:134-140. doi:10.1016/j.canlet.2019.11.013
Li M, Jin C, Xu M, Zhou L, Li D, Yin Y. Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling. Cell Commun Signaling. 2017;15:52. doi:10.1186/s12964-017-0208-8
Li R, Chen G, Dang Y, et al. Upregulation of ATIC in multiple myeloma tissues based on tissue microarray and gene microarrays. Int J Lab Hematol. 2021;43:409-417. doi:10.1111/ijlh.13397
Niu N, Zeng J, Ke X, et al. ATIC facilitates cell growth and migration by upregulating myc expression in lung adenocarcinoma. Oncol Lett. 2022;23:131. doi:10.3892/ol.2022.13251
Wu YJ, Chen HM, Wu TT, Wu JS, Chu RM, Juang RH. Preparation of monoclonal antibody bank against whole water-soluble proteins from rapid-growing bamboo shoots. Proteomics. 2006;6:5898-5902. doi:10.1002/pmic.200600278
Ho K, Yeh T, Huang H, et al. Upregulation of phosphorylated HSP27, PRDX2, GRP75, GRP78 and GRP94 in acquired middle ear cholesteatoma growth. Int J Mol Sci. 2013;14:14439-14459. doi:10.3390/ijms140714439
Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14:159-169. doi:10.1016/j.devcel.2008.01.013
Kavanagh E, Joseph B. The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochem Biophys Acta. 2011;1816:50-56. doi:10.1016/j.bbcan.2011.03.002
Creff J, Besson A. Functional versatility of the CDK inhibitor p57(Kip2). Front Cell Dev Biol. 2020;8:584590. doi:10.3389/fcell.2020.584590
Ni L, Guan K, Zalkin H, Dixon JE. De novo purine nucleotide biosynthesis: cloning, sequencing and expression of a chicken PurH cDNA encoding 5-aminoimidazole-4-carboxamide-ribonucleotide transformylase-IMP cyclohydrolase. Gene. 1991;106:197-205. doi:10.1016/0378-1119(91)90199-l
Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009;69:5467-5474. doi:10.1158/0008-5472.CAN-08-4979
Asby DJ, Cuda F, Beyaert M, Houghton FD, Cagampang FR, Tavassoli A. AMPK activation via modulation of de novo purine biosynthesis with an inhibitor of ATIC homodimerization. Chem Biol. 2015;22:838-848. doi:10.1016/j.chembiol.2015.06.008
Brooks HB, Meier TI, Geeganage S, et al. Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models. Sci Rep. 2018;8:15458. doi:10.1038/s41598-018-33453-4
Park JA, Shin HY. ATIC gene polymorphism and histologic response to chemotherapy in pediatric osteosarcoma. J Pediatr Hematol Oncol. 2017;39:e270-e274. doi:10.1097/MPH.0000000000000802
Cereja Pantoja KBC, Azevedo TCB, Carvalho DC, et al. Impact of variants in the ATIC and ARID5B genes on therapeutic failure with imatinib in patients with chronic myeloid leukemia. Genes. 2022;13:330. doi:10.3390/genes13020330
Wu CC, Chen HC, Chen SJ, et al. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics. 2008;8:316-332. doi:10.1002/pmic.200700819
Oliemuller E, Peláez R, Garasa S, et al. Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC. Int J Cancer. 2013;132:1986-1995. doi:10.1002/ijc.27881
Zou J, Huang R, Chen Y, et al. Dihydropyrimidinase like 2 promotes bladder cancer progression via pyruvate kinase M2-Induced aerobic glycolysis and Epithelial-Mesenchymal transition. Front Cell Dev Biol. 2021;9:641432. doi:10.3389/fcell.2021.641432
Li F, Ling Q, Lian J, et al. Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia. Cancer Med. 2023;12:8319-8330. doi:10.1002/cam4.5531
Abu Rmaileh A, Solaimuthu B, Khatib A, et al. DPYSL2 interacts with JAK1 to mediate breast cancer cell migration. J Cell Biol. 2022;221:e202106078. doi:10.1083/jcb.202106078
Samland AK, Sprenger GA. Transaldolase: from biochemistry to human disease. Int J Biochem Cell Biol. 2009;41:1482-1494. doi:10.1016/j.biocel.2009.02.001
Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39:347-354. doi:10.1016/j.tibs.2014.06.005
Leduc CA, Crouch EE, Wilson A, et al. Novel association of early onset hepatocellular carcinoma with transaldolase deficiency. JIMD Rep. 2014;12:121-127. doi:10.1007/8904_2013_254
Yi H, Zheng X, Song J, Shen R, Su Y, Lin D. Exosomes mediated pentose phosphate pathway in ovarian cancer metastasis: a proteomics analysis. Int J Clin Exp Pathol. 2015;8:15719-15728.
Silvers CR, Miyamoto H, Messing EM, Netto GJ, Lee YF. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget. 2017;8:91199-91208. doi:10.18632/oncotarget.20043
Wu YR, Lee YC, Li WM, et al. High transaldolase 1 expression predicts poor survival of patients with upper tract urothelial carcinoma. Pathol Int. 2021;71:463-470. doi:10.1111/pin.13101
Liang R, Li X, Zhu X. Deciphering the roles of IFITM1 in tumors. Mol Diagn Ther. 2020;24:433-441. doi:10.1007/s40291-020-00469-4
Fumoto S, Shimokuni T, Tanimoto K, et al. Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int J Oncol. 2008;32:413-423.
Lee HR, No HK, Ryu CJ, Park HJ. Brahma-related gene 1-associated expression of 9-27 and IFI-27 is involved in acquired cisplatin resistance of gastric cancer cells. Mol Med Rep. 2013;8:747-750. doi:10.3892/mmr.2013.1576
Zhang K, Jiang K, Hong R, et al. Identification and characterization of critical genes associated with tamoxifen resistance in breast cancer. PeerJ. 2020;8:e10468. doi:10.7717/peerj.10468
Yang K, Hu H, Wu J, et al. Letter to the editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma. Mol Cancer. 2023;22:25. doi:10.1186/s12943-023-01729-7
Suarez-Cabrera C, Estudillo L, Ramón-Gil E, et al. BlaDimiR: a urine-based miRNA score for accurate bladder cancer diagnosis and follow-up. Eur Urol. 2022;82:663-667. doi:10.1016/j.eururo.2022.08.011